UBS Group
CNLM

UBS Group’s CB PHARMA ACQUISISTION CORP SHS (CYM) CNLM Stock Holding History

UBS Group’s Portfolio CNLM Stock Details CNLM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,233
Closed -$12K – 8669
2015
Q4 		$12K Buy
+1,233
New +$12.2K ﹤0.01% 7200

Other funds holding CNLM

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group's CNLM Position: Q1 2016 in Review

UBS Group sold out of CB PHARMA ACQUISISTION CORP SHS (CYM) (CNLM) in Q1 2016, closing a stake of 1,233 shares — an estimated $12K sold.

UBS Group first reported a position in CNLM in Q4 2015 and held it in 1 quarter. The position peaked at $12K in Q4 2015. 8 funds tracked by Wall St. Rank hold CNLM as of Q1 2016.

  • UBS Group reported no remaining CB PHARMA ACQUISISTION CORP SHS (CYM) position as of Q1 2016 after selling out during the quarter.
  • UBS Group sold 1,233 CB PHARMA ACQUISISTION CORP SHS (CYM) shares in Q1 2016, an estimated $12K.
  • UBS Group first reported a position in CB PHARMA ACQUISISTION CORP SHS (CYM) in Q4 2015 and held it in 1 quarter.
  • UBS Group's CB PHARMA ACQUISISTION CORP SHS (CYM) position peaked at $12K in Q4 2015.
  • 8 funds tracked by Wall St. Rank held CB PHARMA ACQUISISTION CORP SHS (CYM) as of Q1 2016.

Based on UBS Group's 13F filing for Q1 2016, filed 12 May 2016.